**ПЕРЕЛІК**

**ЛІКАРСЬКИХ ЗАСОБІВ ЩОДО ЯКИХ ЗАВЕРШЕНО РОЗГЛЯД РЕЄСТРАЦІЙНИХ МАТЕРІАЛІВ ПРО ВНЕСЕННЯ ЗМІН ДО РЕЄСТРАЦІЙНИХ МАТЕРІАЛІВ ПРОТЯГОМ ДІЇ РЕЄСТРАЦІЙНОГО ПОСВІДЧЕННЯ НА ЛІКАРСЬКІ ЗАСОБИ, ЯКІ ЗАРЕЄСТРОВАНІ КОМПЕТЕНТНИМИ ОРГАНАМИ СПОЛУЧЕНИХ ШТАТІВ АМЕРИКИ, ШВЕЙЦАРСЬКОЇ КОНФЕДЕРАЦІЇ, ЯПОНІЇ, АВСТРАЛІЇ, КАНАДИ, ЛІКАРСЬКИХ ЗАСОБІВ, ЩО ЗА ЦЕНТРАЛІЗОВАНОЮ ПРОЦЕДУРОЮ ЗАРЕЄСТРОВАНІ КОМПЕТЕНТНИМ ОРГАНОМ
ЄВРОПЕЙСЬКОГО СОЮЗУ**

| ***№ п/п*** | ***Назва лікарського засобу*** | ***Форма випуску (лікарська форма, упаковка)*** | ***Заявник*** | ***Країна*** | ***Виробник*** | ***Країна*** | ***Реєстраційна процедура*** | ***Умови відпуску*** | ***Номер реєстраційного посвідчення*** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **СОЛІКВА** | розчин для ін`єкцій, 100 Од./мл+50 мкг/мл, №3 або №5: по 3 мл у картріджі, вмонтованому в одноразову шприц-ручку; по 3 або по 5 шприц-ручок в картонній коробці. Голки в упаковку не включені | ТОВ "Санофі-Авентіс Україна" | Україна | Санофі-Авентіс Дойчланд ГмбХ  | Німеччина | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol Type II: To implement changes to the manufacturing process at several steps (adaptation of selected process parameters of subsequent steps to the purer cleavage solution and higher yield) of insulin glargine drug substance, with the introduction of an alternative recombinant trypsin variant TRY-1052 to the current trypsin variant S172A for the cleavage of pre pro-insulin glargine in step 9 of the process and related process adaptations: - Step 9: adaptation of pH range during cleavage, addition of CaCl2 to enhance cleveage reaction and taylored trypsin concentration for the newly introduced trypsin variant. - Step 10: adaptation of column loading and pH. - Step 11: adaptation of column loading, pH, gradient and 1-propanol content. - Step 12: adaptation of column loading. Wild type trypsin will be deleted from the applications as not used anymore. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size Type IB: To increase the batch size linked to process yield improvement for TRY 1052: one fermentation run will yield one or two final batches (due to equipment capacity), which can be traced back to a single bioreactor. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation Type IB: To extended the storage of crystalline insulin glargine after reversed phase chromatography (step 12): the change proposes to establish an extended storage of crystalline insulin glargine at ? 8°C from today 14 days to up to 60 days, supported by validation data. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation Type IB: Ti implement other minor updates to the manufacturing process description related to results gained from additional process knowledge and studies: - Step 3: adaptation of pH. - Step 8: adaptation of L-cysteine concentration and pH. - Step 10: adaptation of linear flow elution. - Step 11: adaptation of column loading & pH, adjustment of 1-propanol content in eluate, more concise description of gradient. - Step 12: adaptation of column loading & pH of elution buffer, more concise description of gradient, adjustments of crystallization parameters. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation Type IB: To implement a change referring to the upgrade of Critical Process Parameters, related to additional process knowledge and studies CPP 3.2., CPP 8.1, CPP 9.1, CPP10.1, CPP 11.1, CPP 11.2, CPP 11.3, CPP 11.4, CPP 12.1, CPP12.2, CPP12.3, CPP12.4, CPP 13.1. | *за рецептом* | UA/16774/01/01 |
|  | **СОЛІКВА** | розчин для ін`єкцій, 100 Од./мл+33 мкг/мл, №3 або №5: по 3 мл у картріджі, вмонтованому в одноразову шприц-ручку; по 3 або по 5 шприц-ручок в картонній коробці. Голки в упаковку не включені | ТОВ "Санофі-Авентіс Україна" | Україна | Санофі-Авентіс Дойчланд ГмбХ  | Німеччина | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol Type II: To implement changes to the manufacturing process at several steps (adaptation of selected process parameters of subsequent steps to the purer cleavage solution and higher yield) of insulin glargine drug substance, with the introduction of an alternative recombinant trypsin variant TRY-1052 to the current trypsin variant S172A for the cleavage of pre pro-insulin glargine in step 9 of the process and related process adaptations: - Step 9: adaptation of pH range during cleavage, addition of CaCl2 to enhance cleveage reaction and taylored trypsin concentration for the newly introduced trypsin variant. - Step 10: adaptation of column loading and pH. - Step 11: adaptation of column loading, pH, gradient and 1-propanol content. - Step 12: adaptation of column loading. Wild type trypsin will be deleted from the applications as not used anymore. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size Type IB: To increase the batch size linked to process yield improvement for TRY 1052: one fermentation run will yield one or two final batches (due to equipment capacity), which can be traced back to a single bioreactor. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation Type IB: To extended the storage of crystalline insulin glargine after reversed phase chromatography (step 12): the change proposes to establish an extended storage of crystalline insulin glargine at ? 8°C from today 14 days to up to 60 days, supported by validation data. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation Type IB: Ti implement other minor updates to the manufacturing process description related to results gained from additional process knowledge and studies: - Step 3: adaptation of pH. - Step 8: adaptation of L-cysteine concentration and pH. - Step 10: adaptation of linear flow elution. - Step 11: adaptation of column loading & pH, adjustment of 1-propanol content in eluate, more concise description of gradient. - Step 12: adaptation of column loading & pH of elution buffer, more concise description of gradient, adjustments of crystallization parameters. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation Type IB: To implement a change referring to the upgrade of Critical Process Parameters, related to additional process knowledge and studies CPP 3.2., CPP 8.1, CPP 9.1, CPP10.1, CPP 11.1, CPP 11.2, CPP 11.3, CPP 11.4, CPP 12.1, CPP12.2, CPP12.3, CPP12.4, CPP 13.1. | *за рецептом* | UA/16775/01/01 |
|  | **КЕНГРЕКСАЛ** | порошок для концентрату для розчину для ін'єкцій / інфузій, 50 мг; по 50 мг у флаконі, по 10 флаконів в картонній коробці  | К'єзі Фармас'ютікелз ГмбХ | Австрія | виробництво, контроль якості та первинне пакування: Патеон Італія С.п.А., Італiя; вторинне пакування: К'єзі Фармацеутиці С.п.А., Італія; випуск серії: Хальса Фарма ГмбХ, Німеччина | Італія/Німеччина | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Type II: Submission of an updated RMP (version 3.1) in order to revise the objectives, the safety concerns to address and the milestones for a study listed as category 3 in the RMP: a multicentre retrospective observational study of patients undergoing percutaneous coronary intervention (PCI) who receive cangrelor and transition to either clopidogrel, prasugrel or ticagrelo (ARCANGELO – Italian prospective study on cangrelor). The protocol synopsis of the PASS is included in the Annex to the RMP. In addition, the RMP and the list of safety concerns are revised in accordance with the GVP Module V guideline (rev. 2). | *за рецептом* | UA/17224/01/01 |